Pfizer Talzenna & Xtandi Improve Survival in mCRPC
Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...
Allogene Therapeutics Publishes Durable Response Data from Phase 1 Trials of ALLO-501 in R/R LBCL
Allogene Therapeutics announced positive results from its Phase 1 ALPHA and ALPHA2 clinical trials of cema-cel, an allogeneic CAR...
UCB Bimzelx Poised to Disrupt Psoriatic Arthritis Market
UCB’s Bimzelx (bimekizumab), a dual IL-17A/IL-17F inhibitor for psoriatic arthritisarthritis (PsA), is demonstrating strong early adoption among rheumatologists just...
BioCardia Completes Low-Dose Cohort Enrollment in CardiALLO Trial
BioCardia completed enrollment and dosing in the low-dose cohort of its CardiALLO™ Phase I/II trial. This trial investigates allogeneic...
AskBio Gene Therapy Trial for Heart Failure Begins in Europe
AskBio, a Bayer subsidiary, has initiated the European arm of its Phase 2 GenePHIT trial for AB-1002, a gene...
NKGen Biotech Publishes Promising Alzheimer’s Drug Trial Results
NKGen Biotech announced the publication of Phase 1 clinical trial results for troculeucel, an NK cell therapy for Alzheimer’s...
Pliant Announces Next Steps for Beacon-IPF Trial
Pliant Therapeutics has convened an external expert panel to analyze data from its paused BEACON-IPF Phase 2b trial of...
Bio-Path Holdings’ Key Clinical Breakthroughs
Bio-Path Holdings provided updates on two clinical trials: BP1001-A for solid tumors and prexigebersen for acute myeloid leukemia (AML)....
Advancing Cancer Care: The Impact of Illinois’ New Bill of Rights
In this interview, we conversed with Pete Govorchin, President, City of Hope® Cancer Center Chicago and Edward S. Kim,...
CertisAI Predictive Oncology Intelligence Platform Awarded US Patent
Certis Oncology Solutions received patent approval for its predictive AI/ML platform, CertisAI™, designed to forecast drug response using gene...